Physician profile
Kathy Loo
NPI 1922795731
$2,512.92
in general payments reported to CMS, 2019-2025
19 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.95 · 2024: $737 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.15 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $389.25 | 2024-2025 | Airsupra, Farxiga |
| Genzyme Corporation | $306.42 | 2024-2025 | |
| Amgen INC. | $273.74 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $220.01 | 2025 | |
| Exact Sciences Corporation | $136.66 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $116.58 | 2024 | Nexletol, Nexlizet |
| Shield Therapeutics INC | $73.02 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $72.73 | 2025 | Gemtesa |
| Pfizer INC. | $49.70 | 2025 | |
| Novartis Pharmaceuticals Corporation | $46.65 | 2025 | |
| Gilead Sciences, INC. | $33.56 | 2025 | |
| Astellas Pharma US INC | $28.68 | 2025 | Veozah |
| Lilly USA, LLC | $25.75 | 2025 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.34 | 2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $18.52 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $13.82 | 2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Azurity Pharmaceuticals, INC. | $13.54 | 2024 | |
| Hologic Sales and Service, LLC | $12.80 | 2023 | Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Loo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.